In this edition, FDA approves Vanflyta for newly diagnosed AML; liso-cel could have 'best shot' at remission for double refractory CLL; mortality factors among cancer survivors and more.
Read the full coverage here:
FDA approves Vanflyta for newly diagnosed acute myeloid leukemia
VIDEO: Liso-cel could have 'best shot' at remission for double refractory CLL
Community affluence, insurance mediate CV mortality among Black, white cancer survivors
VIDEO: MOLTO study probes combination therapy in Richter syndrome
Gilead terminates phase 3 trial of magrolimab regimen for myelodysplastic syndrome
References:
ASCO Annual Meeting
ASCO Annual Meeting
Press Release
Press Release
Sung H, et al. Int J Epidemiol. 2023;doi:10.1093/ije/dyad097.
